SANNINO, ANNA (2018) IMPACT OF CALCIFIC MITRAL STENOSIS ON SURVIVAL IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT. [Tesi di dottorato]

[img]
Anteprima
Testo
Sannino_Anna_XXXIciclo.pdf

Download (919kB) | Anteprima
[error in script] [error in script]
Tipologia del documento: Tesi di dottorato
Lingua: English
Titolo: IMPACT OF CALCIFIC MITRAL STENOSIS ON SURVIVAL IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Autori:
AutoreEmail
SANNINO, ANNAanna.sannino@icloud.com
Data: 3 Dicembre 2018
Numero di pagine: 28
Istituzione: Università degli Studi di Napoli Federico II
Dipartimento: Scienze Biomediche Avanzate
Dottorato: Medicina clinica e sperimentale
Ciclo di dottorato: 31
Coordinatore del Corso di dottorato:
nomeemail
BEGUINOT, FRANCESCO[non definito]
Tutor:
nomeemail
TRIMARCO, BRUNO[non definito]
Data: 3 Dicembre 2018
Numero di pagine: 28
Parole chiave: mitral stenosis; aortic valve
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/11 - Malattie dell'apparato cardiovascolare
Depositato il: 19 Dic 2018 12:45
Ultima modifica: 30 Giu 2020 08:48
URI: http://www.fedoa.unina.it/id/eprint/12463

Abstract

Objectives. This study was performed to investigate the prevalence and impact on survival of baseline calcific mitral stenosis (MS) in patients undergoing transcatheter aortic valve replacement (TAVR) due to the presence of severe symptomatic aortic stenosis (AS). Methods. This retrospective study included 928 consecutive patients with severe, symptomatic AS undergoing TAVR in two institutions, from January 2012 to August 2016. Mean follow-up was 40.8±13.9 months. Results. Based on mean mitral gradients (MMG) at baseline, 3 groups were identified: normal-mild, MMG<5 mmHg (n=737, 81.7%); moderate MMG5 and <10 mmHg (n=147, 16.3%); severe MMG10 mmHg (n=17, 1.9%). These latter were more frequently women, with a smaller body surface area, a higher prevalence of atrial fibrillation, chronic obstructive pulmonary disease and previous history of CABG/PCI. At baseline, patients with MMG10 mmHg compared with 5 and <10 mmHg and normal patients exhibited a lower mitral valve area (2.4±0.94 vs 2.1±0.86 vs 1.5±0.44 cm2) a lower prevalence of MR2+ (5.9% vs 28.6% and 15.6%, p<0.0001), a higher prevalence of severe mitral annular calcium (70.6% vs 45.6% and 13.0%, p<0.0001) and a higher systolic pulmonary arterial pressure (50.6±12.1 vs 47.2±14.5 and 41.6±14.4, p<0.0001). Despite the low prevalence of MMG10 mmHg, these patients experienced higher 5-year mortality compared to the other groups (adjusted Hazard Ratio: 2.91, 95% Confidence Interval [CI]:1.17-7.20, p=0.02). Conclusions. Severe calcific MS is uncommon in patients undergoing TAVR. However, its presence is associated with higher long-term mortality whereas moderate MS is not. The presence of severe calcific MS might identify a subgroup of patients in whom a double valve intervention should be considered.

Downloads

Downloads per month over past year

Actions (login required)

Modifica documento Modifica documento